|
See related Peg-Intron information |
|
|
|
Manufacturer |
MSD |
|
Distributor |
Hong Kong: DKSH/Macau: Four Star |
|
Contents |
Recombinant interferon α-2b conjugated w/ monomethoxy polyethylene glycol. |
|
Indications |
Treatment of chronic hepatitis C in patients ≥18 yr w/ compensated liver disease; elevated transaminases w/o liver decompensation; positive for serum HCV-RNA including naive patients w/ clinically stable HIV co-infection & combination w/ ribavirin in naive patients who have failed previous treatment w/ interferon α (pegylated or nonpegylated) & ribavirin combination therapy or interferon α monotherapy. |
|
Dosage |
Adult ≥18 yr Monotherapy 0.5 or 1 mcg/kg SC once wkly for at least 6 mth. Combination therapy 1.5 mcg/kg SC once wkly in combination w/ ribavirin cap (800-1,400 mg/day). |
|
Contraindications |
Hypersensitivity. Autoimmune hepatitis or history of autoimmune disease. Decompensated liver disease. Men whose female partners are pregnant & patient w/ CrCl <50 mL/min when used in combination with ribavirin. Pregnancy. |
|
Special Precautions |
Existence of or history of severe psychiatric conditions, history of CHF, MI &/or previous arrhythmic disorders, acute hypersensitivity reactions, renal & hepatic impairment, pulmonary changes, autoimmune disease, thyroid changes, dental & periodontal disorders, metabolic disturbances, psoriasis or sarcoidosis. Patients w/ low CD4 counts. Maintain adequate hydration since hypotension related to fluid depletion may occur. Ocular changes. Periodic visual exam during therapy is recommended. Monitor lipid levels. May impair ability to drive or operate machinery. Lactation. Childn <18 yr. |
|
Adverse Drug Reactions |
Very common: Pain/inflammation at the inj site, fatigue, rigors, fever, depression, arthralgia, nausea, alopecia, musculoskeletal pain, irritability, flu-like symptoms, insomnia, diarrhea, abdominal pain, asthenia, pharyngitis, decreased wt, anorexia, anxiety, impaired conc, dizziness, inj site reaction, tachycardia, rhinitis, taste perversion. Common: Pruritus, dry skin, malaise, increased sweating, right upper quadrant pain, neutropenia, leukopenia, anemia, rash, vomiting, dry mouth, emotional lability, nervousness, dyspnea, viral infection, somnolence, thyroid disorders, chest pain, dyspepsia, flushing, paresthesia, coughing, agitation, sinusitis, hypertonia, hyperesthesia, blurred vision, confusion, flatulence, decreased libido, erythema, eye pain, apathy, hypoesthesia, loose stool, conjunctivitis, nasal congestion, constipation, vertigo, menorrhagia, menstrual disorder, hypotension, syncope, HTN, lacrimal gland disorder, tremor, gingival bleeding, glossitis, stomatitis, ulcerative stomatitis, hearing impairment/loss, tinnitus, palpitation, thirst, aggressive behavior, fungal infection, prostatitis, otitis media, bronchitis, resp disorder, rhinorrhea, eczema, abnormal hair texture, photosensitivity reaction, lymphadenopathy.
View ADR Monitoring Form |
|
Drug Interactions |
Drugs metabolized by CYP2C8/9 & CYP2D6, nucleoside analogs (eg zidovudine, stavudine) highly active antiretroviral therapy.
View more drug interactions with Peg-Intron |
|
Pregnancy Category (US FDA) |
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or embryocidal or other) and there are no controlled studies in women or studies in women and animals are not available. Drugs should be given only if the potential benefit justifies the potential risk to the foetus. |
|
ATC Classification |
L03AB05 - interferon alfa-2b ; Belongs to the class of interferons. Used as immunostimulants. |
|
Presentation/Packing |
|
Form |
Packing |
Photo |
|
Peg-Intron powder for injection |
|
Peg-Intron 80 mcg x 1's |
|
Peg-Intron 120 mcg x 1's |
|
|
Peg-Intron pre-filled pen |
|
Peg-Intron 50 mcg x 1's |
|
Peg-Intron 80 mcg x 1's |
|
Peg-Intron 120 mcg x 1's |
|
|
|
Manufacturer: |
MSD |
|
Distributor: |
Hong Kong: DKSH
Macau: Four Star |
|
|
|
